All News

Poor visualization techniques can oversimplify reality and make data less potent.

Mirum Pharmaceuticals’ acquisition of Bluejay Therapeutics adds brelovitug to its pipeline, positioning the company for a potential first approved treatment for chronic hepatitis delta virus while reinforcing its focus on late-stage rare liver disease development.

In today’s Pharmaceutical Executive Daily, tariff uncertainty triggers a short-term surge in pharmaceutical manufacturing activity, workforce burnout threatens the stability of the blood supply, and industry leaders assess whether artificial intelligence in pharma is reaching a critical inflection point.

Global pharmaceutical production surged in 2025 due to tariff-driven front-loading but is expected to slow as trade uncertainty, patent expirations, pricing pressure, and shifting industrial policy reshape the industry’s growth, investment, and supply chain strategies.

Persistent blood shortages compounded by widespread laboratory staffing burnout and vacancies are straining transfusion medicine, making investment in lab workforces critical to safeguarding patient access to lifesaving blood supplies.

In today’s Pharmaceutical Executive Daily, the World Health Organization finalizes the United States’ withdrawal from the global health body, Bristol Myers Squibb enters an $850 million collaboration with Janux Therapeutics to advance tumor-activated cancer therapies, and industry leaders examine how real-world data is increasingly shaping patient access decisions.

The decision is based on President Trump’s executive order issued last year.

In the final part of his conversation with Pharmaceutical Executive, Ken Keller discusses what his expectations are following the healthcare conference.

Janux Therapeutics has partnered with Bristol Myers Squibb in a global licensing and collaboration deal to advance a tumor-activated therapy for solid tumors, combining Janux’s early-stage platform innovation with Bristol Myers Squibb’s clinical and commercial scale.

Novavax and Pfizer announce a non-exclusive licensing deal giving Pfizer access to Novavax’s Matrix-M adjuvant technology, a move that underscores Novavax’s shift toward partnership-driven growth.

The acquisition includes several gummy products that are expected to begin launching in 2026.

Anders Romare, Advisory Board Member, causaLens, and former Novo Nordisk CDIO, outlines why artificial intelligence represents a structural turning point for the pharmaceutical industry.

Regulatory approval is no longer simply representative of the finish line—but instead can serve as a key launching point to evidence-driven insights that create more timely and broader product access.

In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of RAPT Therapeutics, Atkins launches a new partnership to better understand consumer mindsets around GLP-1 use, and Shionogi agrees to acquire Pfizer’s remaining stake in ViiV Healthcare.

When researchers excluded studies that did not use proper methods to collect data, the results showed no connection between the medication and genetic disorder.

Shionogi and GSK are streamlining ViiV Healthcare’s ownership by buying out Pfizer’s 11.7% stake, leaving the HIV specialist jointly owned by its two long-time partners.

The AI dilemma facing biopharma—and what’s at risk.

A comparison of 2024 and 2025 bio/pharma employment survey results indicates that industry professionals face eroding security, polarized satisfaction, and rising attrition risk.

GSK is strengthening its allergy and immunology pipeline with a $2.2 billion acquisition of RAPT Therapeutics which includes ozureprubart, a long-acting, potentially best-in-class anti-IgE antibody.

In today’s Pharmaceutical Executive Daily, Henlius enters a global exclusive licensing agreement with UMAb Biopharma for a potential best-in-class anti-IL-1RAP antibody, a new report highlights drugmakers raising list prices amid pricing agreements with the Trump administration, and Novartis urges governments to address mounting global trade policy challenges impacting the biopharmaceutical industry.

Atkins is leveraging a partnership with reality TV star Heather Gay and early clinical trial data to reposition nutrition as a critical, science-backed complement to GLP-1 weight-loss therapies.

The biggest and most important takeaways from the recent JP Morgan Healthcare Conference.

Shanghai Henlius used the 2026 J.P. Morgan Healthcare Conference to announce an exclusive global license for a potentially best-in-class anti-IL-1RAP monoclonal antibody that expands the company beyond oncology into high-unmet-need autoimmune and inflammatory diseases.

Jeff Liter, CEO of Luminary Therapeutics, discusses the importance of demonstrating clinical evidence at the JP Morgan Healthcare Conference.

Despite pledges to lower drug costs through Trump-backed pricing deals and direct-to-patient programs, pharmaceutical companies entered 2026 by raising list prices on hundreds of brand-name medicines, underscoring the limited impact of recent policy efforts on the broader U.S. drug pricing landscape.

Ken Keller, Daiichi Sankyo’s head of global oncology and CEO of US operations, discusses the importance of bringing quality data to the JP Morgan Healthcare Conference.

The company composed a letter addressed to global governments to harness competitiveness and innovation to navigate the current global trade economy.

Daiichi Sankyo’s US CEO and head of global oncology Ken Keller explains what his expectations are for JP Morgan prior to the conference.